November #107 : In Stores-and In Store - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Vote '04-Who’s better for people with HIV?

Vote '04-We Have Issues

Vote '04-4 More Years?!?

Vote '04-Who Ya For?

Vote '04-Full-Frontal Election

Vote '04-Hot Seats

1,2,3...ENTRY!

Back to School

When Life Hands You Lemons...

One Hot Tomato

Microbicide Update

Sayonara, Suckers

Waiting to Exhale

Pos & Neg

Fit to Print

Website of the Month

Milestones

Meet Your Host

Briefs

In Stores-and In Store

Brush With Nausea

Rebel With a Cause

A Woman’s Guide to Living With HIV Infection

Those Other Pills

Marijuana Mama

Found a cure

Founder's Letter

Mailbox

Senior Class

Earthwatch

Inside Story



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

November 2004

In Stores-and In Store

by Tim Horn

This year, drug companies have shoehorned daily fistfuls of meds into fewer pills and doses. Next year. they'll focus on resistance-fighting compounds

If only the names were simple Truvada and Epzicom, a duo of two-in-one combo nukes, have hit pharmacy shelves, challenging Combivir (3TC/AZT). Truvada, Gilead Sciences’ fixed-dose combination (FDC) capsule, mixes 300 mg Viread (tenofovir) with 200 mg Emtriva (FTC). GlaxoSmithKline’s Epzicom combines 600 mg Ziagen (abacavir) and 300 mg Epivir (3TC). Both FDCs conveniently require only one pill daily, taken typically with a non-nuke or protease inhibitor (PI). “The only thing better would be to get a full regimen into a fixed-dose combination,” says Tom Gegeny of the AIDS Treatment Activists Coalition.

Hold that thought Gilead, Bristol-Myers Squibb and Merck say they’re teaming up on a once-daily Sustiva (efavirenz)/Viread/Emtriva tablet to meet adherence demands in nations rich and poor. (Merck markets efavirenz in some parts of the world.)

Not so simple Abbott filed for FDA approval to study Kaletra (lopinavir/ritonavir) as a once-daily—but only for new-to-HAART HIVers (once-a-day doses may not keep drug levels consistent enough to overcome resistant HIV in others). Another party pooper: In tests, the once-a-day sent more people running for the loo than its twice-daily ancestor.

Alive in 2005 Tipranavir, Boehringer Ingelheim’s PI, is likely to be the only new HAART med approved next year—along with its doesn’t-play-well-with-other-PIs, needs-a-big-boost limitations (see “Trouble for Tipranavir,” POZ, September 2004).

Coming Attraction Reverset, from HIV newcomers Pharmasset and Incyte, may help HIVers with multi-nuke resistance. The new nuke trounces many resistant HIV strains but can cause—and is less active against—the dreaded K65R mutation (think Viread resistance). In a recent study, eight much-treated HIVers added once-daily Reverset to a failing regimen. Ten days later, four had undetectable viral loads; 20 days after the drug was stopped, viral loads were still below their pre-Reverset levels. But “we need long-term data,” Gegeny says. “Many promising candidates have fallen by the wayside when data from larger studies show unexpected and unsafe results.” Phase II studies are underway, with larger Phase III studies expected next summer.




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    fokisi
    Long Beach
    California


    zeze42
    Bay Area - Peninsula
    California


    cortaza100
    Oakland
    California


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.